Trophos Appoints JSB-Partners as Global Partnership Advisor
Published: Jul 23, 2012
JSB Partners has been selected by Trophos to assist the company in executing its business development objectives. These aim to put in place strategic partnerships for Trophos’ advanced clinical development programs:
• Olesoxime, which is presently being tested in a pivotal trial in Spinal Muscular Atrophy (SMA) with results due in the second half of 2013;
• Olesoxime for Multiple Sclerosis (MS) disease progression, with a phase II proof-of-concept trial designed with global MS experts, ready to be initiated leading to results in 2016;
• TRO40303, in an ongoing phase IIa proof-of-concept study in cardiac ischemia-reperfusion injury (IRI), with results due in the first half of 2013
“Trophos has always followed a unique path, forming consortia to work on high medical need orphan or niche indications with no existing treatments,” said Christine Placet, CEO Trophos. “The expertise of world leading specialists within these conditions has contributed to and enhanced the Trophos pipeline. Both the market potential of our candidates - nearly USD two billion, as well as the patients suffering from terrible orphan diseases and conditions, deserve optimal partnerships to advance therapies and cures for these conditions. This is why we have appointed some of the best advisors to help us.”
“There is considerable market potential for the conditions targeted by the Trophos pipeline,” said Michel Gouy, partner, JSB-Partners. “It is critical to find the right partnerships for continued advancement in treatment for these conditions.”
About JSB-Partners - http://www.jsb-partners.com
JSB-Partners is a global transaction advisory firm with a proven history in creating value for its clients. The partners' broad life science and medical backgrounds also include deep and diverse expertise in financial, commercial and strategic business transactions at the global level. JSB has extensive and trusted relationships with pharma/biotech clients and shareholders and a proven partnering process, which allows them to achieve value-maximizing transactions and aligned outcomes for stakeholders. JSB's senior team members are located in the United States, Europe and Japan.
About Trophos SA – http://www.trophos.com
Trophos is a clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology. The company has a novel and proprietary cholesterol oxime based chemistry platform generating a pipeline of drug candidates. The lead product, olesoxime (TRO19622), is in a pivotal clinical study for Spinal Muscular Atrophy (substantially funded by the AFM patient association). Olesoxime is also ready for a phase II proof of concept study in Multiple Sclerosis (MS) disease progression. A second product, TRO40303, is in phase II clinical development to treat cardiac reperfusion injury (as part of an EU funded project, MitoCare). Trophos' mitochondrial pore modulator compounds enhance the function and survival of stressed cells via modulation of dysfunctional mitochondria through interactions at the permeability transition pore (mPTP). Recently published clinical studies support the therapeutic rationale for mitochondria targeted drugs, which Trophos is uniquely placed to exploit.
Trophos, founded in 1999, is based in Marseille, France and currently has 27 employees.
ANDREW LLOYD & ASSOCIATES
Follow us on Twitter: https://twitter.com/ALA_Group
Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND
Tel: +44 1273 675100 Fax: +44 1273 675400
55 rue Boissonade 75014 Paris FRANCE
Tel: +33 1 56 54 07 00 Fax: +33 1 56 54 07 01
INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION